MARKET

EYPT

EYPT

EyePoint
NASDAQ
13.66
-0.05
-0.36%
After Hours: 13.66 0 0.00% 16:40 06/26 EDT
OPEN
13.71
PREV CLOSE
13.71
HIGH
14.07
LOW
13.52
VOLUME
3.55M
TURNOVER
--
52 WEEK HIGH
19.11
52 WEEK LOW
7.94
MARKET CAP
1.15B
P/E (TTM)
-3.9021
1D
5D
1M
3M
1Y
5Y
1D
Jefferies Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
TipRanks · 2d ago
EyePoint Pharmaceuticals Price Target Maintained With a $68.00/Share by Guggenheim
Dow Jones · 2d ago
Guggenheim Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT) and Nuvectis Pharma (NVCT)
TipRanks · 4d ago
EyePoint Stockholders Approve Incentive Plan and Board Slate
TipRanks · 5d ago
EyePoint shareholders approve 4.9 million-share increase to 2023 incentive plan
PUBT · 5d ago
Weekly Report: what happened at EYPT last week (0615-0619)?
Weekly Report · 5d ago
Analysts’ Top Healthcare Picks: Voyager Therapeutics (VYGR), EyePoint Pharmaceuticals (EYPT)
TipRanks · 06/18 09:41
More
About EYPT
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.

Webull offers EyePoint Inc stock information, including NASDAQ: EYPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EYPT stock methods without spending real money on the virtual paper trading platform.